Related Experiment Videos
Medical management of hypercalcaemia
1Department of Medicine and Therapeutics, Aberdeen University Medical School, Foresterhill Hospital.
British Journal of Clinical Pharmacology
|July 1, 1992
Summary
Hypercalcaemia management involves treating the underlying cause or using medications to lower calcium levels. Intravenous bisphosphonates are the primary treatment, with other drugs used for severe or rapid-onset cases.
Area of Science:
- Endocrinology
- Nephrology
- Oncology
Background:
- Hypercalcaemia is a prevalent condition requiring prompt treatment to prevent organ damage and mortality.
- While addressing the root cause is ideal, pharmacological interventions are crucial for symptom control and managing untreatable conditions.
Purpose of the Study:
- To outline current medical therapies for hypercalcaemia.
- To detail the efficacy and application of various antihypercalcaemic agents.
Main Methods:
- Review of established medical treatments for hypercalcaemia.
- Analysis of pharmacological agents targeting bone resorption and renal calcium excretion.
Main Results:
- Intravenous bisphosphonates are the first-line therapy for initial hypercalcaemia management, offering sustained bone resorption inhibition.
- Calcitonin provides rapid but short-term effects, useful in severe cases, often combined with bisphosphonates.
- Intravenous phosphate and corticosteroids have limited or specific roles in hypercalcaemia treatment.
Conclusions:
- Bisphosphonates are central to hypercalcaemia management due to their sustained efficacy.
- Therapeutic choices depend on the severity and desired onset of action, with combination therapy sometimes indicated.